OR WAIT null SECS
April 19, 2018
Johnson & Johnson’s Janssen partners with Bristol-Myers Squibb to advance next-generation therapies for cardiovascular diseases.
The agency has granted breakthrough therapy designation to Roche’s hemophilia therapy for treating hemophilia A in patients without factor VIII inhibitors.
April 17, 2018
According to Alexion, the acquisition will help rebuild its clinical pipeline.
The New York City-based company will relocate to another building in the city.
April 12, 2018
The new facility, to be built in Toronto, Canada, will significantly increase capacity for pediatric and booster vaccines.
April 11, 2018
The biopharmaceutical firm has chosen Rhode Island as the site of its next-generation biomanufacturing plant, which will offer flexibility, speed, and efficiency.
April 09, 2018
The acquisition is expected to accelerate progress towards personalized cancer healthcare.
Roche has acquired a program to develop regenerative therapies for multiple sclerosis.
Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.
Celltrion received complete response letters from FDA for its rituximab and trastuzumab biosimilars.